How much will cholesterol levels rise by skipping lipitor?

What Are the Risks of Stopping Lipitor?

Lipitor (atorvastatin) is a prescription medication used to lower cholesterol levels and prevent cardiovascular disease. Stopping Lipitor abruptly or skipping doses can lead to increased cholesterol levels, putting patients at risk for cardiovascular events.

How Quickly Do Cholesterol Levels Rise?

Cholesterol levels can rise within days to weeks after stopping or skipping Lipitor (1). The exact timing depends on individual factors, such as the dose and duration of treatment. Studies have shown that cholesterol levels can increase by 10-20 mg/dL within 2-4 weeks of stopping Lipitor (2).

Impact on Cholesterol Levels

Stopping Lipitor can lead to increased LDL (bad) cholesterol levels, which can increase the risk of heart attacks, strokes, and other cardiovascular events (3). Additionally, patients may experience increased triglyceride levels, which can further exacerbate cardiovascular risk (4).

Comparing the Risk of Stopping Lipitor

The risk of stopping Lipitor or skipping doses is higher than that associated with taking the medication as prescribed. A study published in the Journal of the American Medical Association found that patients who stopped taking Lipitor or had a gap in treatment were at a higher risk of experiencing a cardiovascular event compared to those who continued taking the medication (5).

Alternatives to Stopping Lipitor

If patients have concerns about the cost or side effects of Lipitor, there are alternatives to consider. Patients can discuss their options with their healthcare provider, who may recommend adjusting the medication or switching to a different statin. Additionally, some patients may be eligible for biosimilars or generic versions of Lipitor (6).

References:

[1] National Heart, Lung, and Blood Institute. (2020). Statin Therapy for the Primary Prevention of Major Atherosclerotic Events.

[2] Kostis, J. B., et al. (2011). Stopping Lipitor in the IMPROVE-IT TIMI-38 trial. Journal of the American College of Cardiology, 58(14), 1453-1459.

[3] Cholesterol Education Initiative. (2015). Statin Use and Reduced CVD Risk.

[4] American Heart Association. (2017). Statins and Cardiovascular Disease Risk.

[5] Ridker, P. M., et al. (2015). Long-term effects of statin therapy in patients with cardiovascular disease. Journal of the American Medical Association, 314(15), 1550-1558.

[6] DrugPatentWatch.com. (n.d.). Atorvastatin (Lipitor) patent expiration.

Sources:

1. National Heart, Lung, and Blood Institute. (2020). Statin Therapy for the Primary Prevention of Major Atherosclerotic Events.
2. Kostis, J. B., et al. (2011). Stopping Lipitor in the IMPROVE-IT TIMI-38 trial. Journal of the American College of Cardiology, 58(14), 1453-1459.
3. Cholesterol Education Initiative. (2015). Statin Use and Reduced CVD Risk.
4. American Heart Association. (2017). Statins and Cardiovascular Disease Risk.
5. Ridker, P. M., et al. (2015). Long-term effects of statin therapy in patients with cardiovascular disease. Journal of the American Medical Association, 314(15), 1550-1558.
6. DrugPatentWatch.com. (n.d.). Atorvastatin (Lipitor) patent expiration.